

Industrial Technology Research Institute (ITRI) and Gemseki Inc. (Gemseki) agreed on the collaboration of licensing activities

Industrial Technology Research Institute (ITRI), the biggest applied technology institution in Taiwan, has entered into an agreement with Gemseki Inc. (Gemseki) for the collaboration on licensing and partnering of ITRI's drug candidates and technologies ("assets"). Under the agreement, Gemseki is conducting licensing and business development activities worldwide for ITRI's assets. Gemseki supports to find strategic partners and helps negotiations for these assets.

Founded by Taiwan government in 1973, ITRI has been renowned for leading innovation to realize a better future society. The institute has valuable drug candidates and technologies in life science fields. Based on its commitment to enhancing social well-being, ITRI has been looking for ways to deliver its innovative R&D results through business development activities worldwide.

Gemseki launched in October 2017 in Japan, as a subsidiary of Shin Nippon Biomedical Laboratories, Ltd. (SNBL), which is a Contract Research Organization (CRO), listed on Tokyo Stock Exchange. Gemseki takes an innovative approach to facilitate licensing and partnering activities by utilizing its web-based platform effectively and efficiently while experienced staff members conduct active business development activities to identify appropriate partners. By utilizing the global network, which SNBL has accumulated through 60 years of CRO services, Gemseki can assist with licensing activities by reaching out to life science communities worldwide, which is often the most difficult aspect of drug development for a company or academia.

Dr. Chii-Wann Lin, ITRI Vice President and General Director of Biomedical Technology and Device Research Laboratories, comments, "ITRI has a lot of good drug candidates and technologies, and we are looking for partners for these assets. Gemseki has built an innovative business model and shares our vision to make innovation happen in the life science industry. Its established global network is also appealing for us, aligning with our strategy of leveraging worldwide resources. With this collaboration, I believe ITRI can expedite the commercialization of our technologies and making contributions to the world."

Mr. Hideyuki Hiramata, President and CEO of Gemseki comments, "It is a great honor to work with ITRI, a prestigious research institution in Taiwan. I am very impressed with ITRI's

R&D capability. Also I am very fascinated by the leadership that Dr. Lin takes to bring more innovation. We will be seeking partnering opportunities for ITRI's great assets by utilizing our global network. We are very excited to be able to contribute to the development of life science industry in Taiwan.”

About Industrial Technology Research Institute (ITRI)

Industrial Technology Research Institute (ITRI) is one of the world's leading technology R&D institutions aiming to innovate a better future for society. Founded in 1973, ITRI has played a vital role in transforming Taiwan's industries from labor-intensive into innovation-driven. It focuses on the fields of Smart Living, Quality Health, and Sustainable Environment.

Over the years, ITRI has incubated over 300 innovative companies, including well-known names such as UMC and TSMC. In addition to its headquarters in Taiwan, ITRI has branch offices in the U.S., Europe, and Japan in an effort to extend its R&D scope and promote opportunities for international cooperation around the world. For more information, please visit <https://www.itri.org/eng>.

About Gemseki, Inc.

As a subsidiary of the Japanese public CRO company, Shin Nippon Biomedical Laboratories, Ltd. (SNBL), Gemseki was launched in October 2017 in Japan. Gemseki takes an innovative approach to facilitate licensing activities by using its web-based platform “Drug Candidate Marketplace” effectively.

Homepage: <https://www.gemseki.com/en/>

Drug Candidate Marketplace: <https://www.gemseki.com/en/drugcandidatemarket>